NASDAQ · ELOX
Eloxx Pharmaceuticals, Inc.
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
Loading market information…
OTC · MTST · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
MetaStat Inc’s quoted price sits in the lower half of its reported 52-week range, 98.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow MetaStat Inc’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MetaStat, Inc., a precision medicine company, focuses on discovering and developing therapeutic and diagnostic treatment solutions for cancer patients. The company is developing novel drug candidates and companion diagnostic tests that target the MENA pathway. Its product candidates include MENA diagnostic assay, a tissue-based quantitative immunofluorescence test that measures expression of the pro-metastatic MENA protein splice-variant; companion diagnostic to predict RTK inhibitor drug responses and anti-microtubule drug responses; liquid blood-based biopsy to enhance cancer diagnosis and optimize patient care; MetaSite Breast assay, an immunohistochemistry test that measures micro-anatomical intravasat at blood vessels within the tumor microenvironment ion sites; and prognostic diagnostic to predict risk of cancer metastasis. The company’s therapeutic targets a critical metastatic pathway in solid tumors responsible for driving tumor resistance and the spread of aggressive cancer. MetaStat, Inc. is based in Boston, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:15 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$13.45+$0.27 (+2.05%)
Eloxx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 42.52% below the high.
$0.00$0.00 (0.0%)
Motus GI Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.8% below the high.
$0.00$0.00 (0.0%)
Modern Technology Corp.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Adhera Therapeutics Inc’s quoted price sits in the lower half of its reported 52-week range, 99.0% below the high.
$0.00$0.00 (0.0%)
Rosetta Genomics Ltd.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
$0.00$0.00 (0.0%)
Sunset Island Group, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Cannabiz Mobile, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.02% below the high.
$0.00$0.00 (0.0%)
Nabriva Therapeutics plc’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
